Research Radartracking 1,316 published studies · 343 human · 8 safety signals · 43 clinical trials · 44 cancer pages · updated Aug 2026Open the Research Map →
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedactinomycin d
Educational only, not medical advice. OncoForge makes no claim that Actinomycin D treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
This case report describes a 17-year-old girl with a very rare ovarian rhabdomyosarcoma. The tumor was diagnosed by imaging, pathology, and immunohistochemistry, and it came back within 3 months after surgery. The authors report that she then received VAC chemotherapy (vincristine, actinomycin D, and cyclophosphamide), and they emphasize the need for earlier diagnosis and more standardized treatment approaches.
Histopathology and immunohistochemical markers (desmin, myogenin, WT1) confirmed ovarian rhabdomyosarcoma.
Recurrence occurred within 3 months after surgical resection.
VAC chemotherapy was given after early relapse.
Limitations: Single-patient case report.; No control group.; No quantitative treatment outcome data reported.; Cannot determine effectiveness of VAC from this report alone.; Focus is diagnostic and descriptive rather than evaluative..
Describes a rare ovarian cancer case and subsequent chemotherapy, but does not evaluate a compound's anticancer effect in a comparative way.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Case reportReported positiveLimited evidenceTier 3 · early humann = 1
European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie · Aug 2001 · Case report
This is a single-case report of a 3-year-old boy with pleuropulmonary blastoma who underwent radical resection (bilobectomy) followed by monthly cycles of ifosfamide, vincristine and actinomycin D for 10 months. Histology showed blastemal and mesenchymal areas with rhabdomyoblastic and liposarcomatous differentiation. The patient was alive and disease-free two years after diagnosis; the authors state the favorable outcome is probably due to the radical resection.
Radical resection of the mass was achieved by bilobectomy.
Histology showed blastemal and mesenchymal areas with focal rhabdomyoblastic and liposarcomatous differentiation.
Monthly cycles of chemotherapy with ifosfamide, vincristine and actinomycin D were given for 10 months after surgery.
The patient was alive and disease-free two years after diagnosis.
Authors suggest complete tumour ablation is essential to prevent local recurrence and that the favourable outcome is probably due to radical resection.
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
What changed recently
The latest additions to Actinomycin D's evidence base, and anything that's been retracted.
Cancers where Actinomycin D reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
These are doses as studied or reported, never a recommendation. The right amount of Actinomycin D depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Doses reported in studies
Pleuropulmonary blastomamonthly cycles for 10 months; specific dose amounts not specified · Case report · Aug 2001
Clinical trials studying Actinomycin D
1 ongoing · 0 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.